STAT Plus: Gene therapies are a hard sell. Bluebird hopes to do better in Europe
RUBY WALLAU FOR STAT
Bluebird Bio is nearing European approval of its first gene therapy for a rare blood disorder. It hopes to move faster there than Novartis.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario